IL-37 fusion protein and methods of making and using same
View Patent ↗The disclosure provides interleukin 37 (IL-37) fusion proteins, methods of making IL-37 fusion proteins including constructs used to express IL-37 fusion proteins, and methods of using IL-37 fusion proteins. In some embodiments, the IL-37 fusion protein includes amino acids 46-206 of isoform B of IL-37 and a heavy chain portion of an antibody.
1. A fusion protein comprising:
a fragment of IL-37, wherein the fragment of IL-37 consists of amino acids 46-206 of isoform B of IL-37 and wherein the fragment of IL-37 consists of SEQ ID NO:2; and
a heavy chain portion of an antibody.
2. The fusion protein of claim 1 , wherein the heavy chain portion of an antibody comprises an IgG Fc region.
3. The fusion protein of claim 1 , wherein the heavy chain portion of an antibody comprises an IgG1 Fc region.
4. The fusion protein of claim 3 , wherein the IgG1 Fc region comprises SEQ ID NO:4.
5. The fusion protein of claim 2 , wherein the IgG Fc region comprises mutations to at least one of a complement C1q binding site and an Fc gamma receptor (FcγR) binding site.
6. The fusion protein of claim 3 , wherein the IgG1 Fc region comprises L234A and L235A (LALA) substitutions.
7. The fusion protein of claim 3 , wherein the IgG1 Fc region comprises SEQ ID NO:5.
8. The fusion protein of claim 1 , the fusion protein comprising a peptide linker.
9. The fusion protein of claim 8 , wherein the peptide linker comprises the amino acid sequence GGGS (SEQ ID NO: 15).
10. The fusion protein of claim 8 , wherein the peptide linker connects the fragment of IL-37 and the heavy chain portion of an antibody.
11. The fusion protein of claim 1 , the fusion protein comprising a signal peptide.
12. The fusion protein of claim 11 , wherein the signal peptide comprises a CD33 signal peptide.
13. The fusion protein of claim 12 , wherein the CD33 signal peptide comprises SEQ ID NO:6.